SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is caught up in election-related volatility, with traders linking the selloff to projected Democratic gains and speculating that tighter AI or data-center rules could pressure technology stocks. Others argue the outcome was already expected, the policy fears are overstated, and the decline may be a buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Projected Democratic gains in the midterms and the prospect of a congressional sweep dominate discussion, with traders treating the results as a political setback for Trump and a bearish catalyst for his media company. The reaction is largely negative, though some supporters argue midterm losses are routine and contest the sweep narrative.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs stronger-than-expected results and upbeat outlook, driven by surging AI and data-center demand, are the main focus. Traders are weighing the growth case against concerns about valuation, cash flow, and election-related risks to data-center expansion, contributing to volatile trading and debate over whether the gains will hold.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Apples warning that memory costs are expected to keep rising has revived the bullish case that tight supply supports pricing for memory makers such as SanDisk. Traders remain divided after a steep selloff: bulls point to persistent AI and data-center demand, while bears see a cyclical memory downturn and question whether the rebound can hold.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Election-related political risk dominates: traders fear Democratic gains could bring scrutiny of Musk, threaten government contracts, or complicate data-center expansion and a potential Tesla merger. Others argue those concerns are overstated and point to SpaceXs AI and Starlink prospects, while bullish buy-the-dip posts contend with bearish warnings about volatility and share supply.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A rebound in semiconductor shares, helped by strong AMD and SMCI results, is lifting SOXL after a sharp selloff tied to election concerns about potential constraints on AI and data-center growth. Traders remain divided between buying the dip on confidence in chip demand and fearing further downside amid political uncertainty and volatility in the leveraged ETF.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Volatility in AI and semiconductor stocks around the U.S. midterm results is driving the conversation: traders debated whether election uncertainty and potential AI or data-center regulation contributed to the selloff, while others saw a sector rebound supported by bargain buying and AMDs strong results. Views remain divided on whether the AI trade is recovering or still under pressure.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

A strong quarterly earnings report and higher full-year sales outlook, driven by AI-server demand, are the main focus. Many traders see the results as bullish, but debate whether thin margins, cash-flow concerns and lingering doubts about management justify the stocks muted reaction; broader tech weakness and election-related fears are also cited as headwinds.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is drawing attention amid volatile trading in AI and semiconductor stocks: traders have linked recent weakness to election fears over possible data-center restrictions, while the rebound has been associated with strong AMD results and Apples warning of rising memory costs. Bulls see tight supply and AI-driven memory demand supporting the outlook; skeptics caution that the rally may fade and memory remains cyclical.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,984.36452344 USD and is up -0.00 over the last 24 hours. It is currently trading on 12773 active market(s) with $23,094,171,945.49 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins pullback is drawing attention amid midterm-election uncertainty and a broader risk-off move, with many traders speculating that a Democratic sweep could weigh on crypto. Others argue politics matter little to Bitcoin and see the dip near support as a buying opportunity, leaving sentiment sharply divided.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics Posts Early Data for Cancer Therapy Complication

Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical response by Day 15.read more...

Seres Therapeutics (NASDAQ:MCRB) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million during the...

Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 200 Day Moving Average   - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell...

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50 Day Moving Average - Here's Why...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling...

Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a research report on Friday...

Seres Therapeutics (NASDAQ:MCRB) Issues Earnings Results

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.76) earnings per share for the quarter, beating analysts...

Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Status update earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - What's Next?

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Should You Sell...

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization.</li><li>The company said following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs.</li><li>Seres noted that its cost-cutting measures are expected to extend its cash runway into the third quarter of 2026.</li></ul>Seres Therapeutics Inc. (MCRB) shares fell more than 21% in Thursday’s pre-market trade after the company announced that it is pausing a planned Phase 2 study, while reducing the headcount by 30% to extend its cash runway.Seres stated that it has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the U.S. Food and Drug Administration (FDA).“As we pursue earlier stage programs with the greatest opportunity, such as those targeting inflammatory bowel disease (IBD), we are exploring collaborations to provide additional capital to the company,” said Thomas DesRosier and Marella Thorell, co-CEOs of Seres.<h2 class="st-heading-2">Why Did Seres Pause The Study?</h2>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization, adding that the Phase 2 study drug substance has already been manufactured.The company said that following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs. At the same time, it will continue to seek funding for the Phase 2 study, Seres said.<h2 class="st-heading-2">Extending Cash Runway</h2>Seres noted that its cost-cutting measures, including workforce reductions, are expected to extend its cash runway into the third quarter (Q3) of 2026.The company said that this will help in supporting the continued development of its programs for inflammatory and immune-related diseases, while also giving it additional time to secure funding for the SER-155 Phase 2 study.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MCRB">Seres Therapeutics</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘high’ levels.One user on Stocktwits said that Seres’ announcement confirms that “there is no one interested to partner” with the company.<stembedurl>https://stocktwits.com/Kenny1207/message/644771398</stembedurl><a href="https://stocktwits.com/symbol/MCRB">MCRB stock</a> is down 51% year-to-date and 75% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/samsung-ships-world-first-commercial-hbm4-memory-module-ai-computing/cZRTlXNR4ra">Samsung Ships First Commercial HBM4 Memory Module, Nvidia’s Vera Rubin Expected To Use It: SSNLF Stock Soars 55%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Seres Therapeutics biotechnology company building, Cambridge, Massachusetts, USA

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

Current Price	$1.96
Prev Close	$1.83
Open	$1.97
Dividend Yield	0.00%
50-Day Moving Average	$3.51
Beta	1.37
Avg. Volume	85,646.22
PE Ratio	-0.86

52-Week High	$29.98
52-Week Low	$1.68
Market Capitalization	$18.19M
EPS (Annual)	$0.6422
Price to Book	0.56
Revenue Per Employee	$11,954.55

Feed

News

Sentiment

Earnings

Fundamentals

Info

MCRB Fundamentals